Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Virtual Targeted Protein Degradation Day hosted by UBS.

Robert Plenge, M.D., Ph.D., Executive Vice President, Chief Research Officer and Head of Research, will take part in a fireside chat on Monday, July 15, 2024. He will answer questions about the company beginning at 11:00 a.m. ET.

Investors and the general public are invited to listen to a live webcast of the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X (formerly Twitter), YouTube, Facebook, and Instagram.

corporatefinancial-news